Gene therapy for macular degeneration: Uses and more
Medical News Today· 1 day agoSeveral gene therapies are undergoing clinical trials. In this article, learn more about gene therapy and its potential role in treating macular ...
Measuring levels of proteins in eye fluid may accurately predict need for lifelong macular ...
Medical Xpress· 2 days agoIn a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found...
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
Zacks via Yahoo Finance· 20 hours agoA potential approval for the 16-week dosing regimen would provide a longer treatment interval and...
2-Year Faricimab Results: 'Visual Gains With Fewer Injections'
Medscape· 4 days agoThe trials compared two dosing regimens of faricimab — including a personalized treatment interval...
NHS delays: Avoidable blindness fears over eye care waits
BBC News· 2 days agoA "tide of avoidable blindness" could sweep Wales if eye care services are not reformed, a...
NVISION® Eye Centers Continues National Expansion
14 WFIE Evansville· 10 hours agoALISO VIEJO, Calif. , June 30, 2022 /PRNewswire/ -- NVISION® Eye Centers is pleased to announce the addition of two retina practices to the NVISION family – Salt Lake Retina in Salt Lake City ...
Apellis (APLS) Expands Deal for Targeted Complement Therapies
MSN News· 3 days agoApellis Pharmaceuticals, Inc. APLS announced that it has expanded its existing research and...
Morphology of en face Haller vessel and macular neovascularization at baseline and 3 months as...
Nature· 6 days agoThe inclusion criteria were age 50 years or older, treatment-naïve nAMD confirmed by multimodal retinal imaging (fluorescein angiography, indocyanine green angiography, and ...
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic...
WFMZ Eastern Pennsylvania and Western New Jersey· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration...
Adverum Biotechnologies Obtains EMA’s Priority Medicines Status For Chronic Eye Disorder Candidate -...
Benzinga· 7 days agoThe European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related ...
Yahoo Web Search
Trending Now
